Persones / Equip Humà

Alvaro Madrid Aris

Buscador de publicacions

Publicacions

  • Planella-Cornudella M, Roca-Saladrigues N, Lopez-Baez V, Jatem-Escalante E, Sole-Mir E, Gomez-Arbones X, Alvaro Madrid Aris and Segarra-Medrano A.

    Lymphocytic expression and IL-2 levels in calcineurin inhibitor-resistant nephrotic syndrome due to focal segmental glomerulosclerosis: Implications for calcineurin inhibitor response.

    nefrologia . 46(1): 501402-501402.

    [doi:10.1016/j.nefroe.2026.501402]

  • Dixon BP, Kavanagh D, Alvaro Madrid Aris, Adams B, Kang HG, Wang E, Garlo K, Ogawa M, Amancha P, Chakravarty S, Heyne N, Kim SH, Cataland S, Yoon SS, Miyakawa Y, Luque Y, Muff-Luett M, Tanaka K and Greenbaum LA.

    Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

    Kidney Medicine . 6(8): 100855-100855. Nº de cites: 20

    [doi:10.1016/j.xkme.2024.100855]

  • Salvia, R, Rico, LG, Bradford, JA, Ward, MD, Olszowy, MW, Martinez, C, Alvaro Madrid Aris, Grifols, JR, Ancochea, A, Gomez-Munoz, L, Vives-Pi, M, Martinez-Caceres, E, Fernandez, MA, Sorigue, M and Petriz, J.

    Fast-screening flow cytometry method for detecting nanoplastics in human peripheral blood

    MethodsX . 10: 102057-102057. Nº de cites: 35

    [doi:10.1016/j.mex.2023.102057]

  • Calzada Y, Revuelta I, Elena Codina Sampera, Alcaraz A, López-Báez V, Paredes D, Pedro Arango Sancho, Palou E, Garcia-Herrera A, Oppenheimer F, Diekmann F and Alvaro Madrid Aris.

    Overcoming limits: First ABO incompatible living donor paired kidney transplant in an hypersensitized pediatric recipient in Spain

    PEDIATRIC TRANSPLANTATION . 26(8): . Nº de cites: 3

    [doi:10.1111/petr.14359]

  • Rodas L, Barnadas E, Pereira A, Castrejon N, Saurina A, Calls J, Calzada Y, Alvaro Madrid Aris, Blasco M, Poch E, García-Herrera A and Quintana LF.

    The Density of Renal Lymphatics Correlates With Clinical Outcomes in IgA Nephropathy

    Kidney International Reports . 7(4): 823-830. Nº de cites: 8

    [doi:10.1016/j.ekir.2021.12.029]

  • Roca N, Jatem E, Abo A, Santacana M, Cruz A, Alvaro Madrid Aris, Fraga G, Martin M, Gonzalez J, Martinez C, Balius A and Segarra A.

    CD44-negative parietal-epithelial cell staining in minimal change disease: association with clinical features, response to corticosteroids and kidney outcome

    Clinical Kidney Journal . 15(3): 545-552. Nº de cites: 7

    [doi:10.1093/ckj/sfab215]

  • Rosales A, Alvaro Madrid Aris, Muñoz M, Dapena JL and Ariceta G.

    Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available

    Frontiers in Pediatrics . 9: 635152-635152. Nº de cites: 5

    [doi:10.3389/fped.2021.635152]

  • Roca N, Alvaro Madrid Aris, Lopez M, Fraga G, Jatem E, Gonzalez J, Martinez C and Segarra A.

    Multidimensional inflammatory and immunological endotypes of idiopathic focal segmental glomerulosclerosis and their association with treatment outcomes.

    Clinical Kidney Journal . 14(7): 1826-1834. Nº de cites: 4

    [doi:10.1093/ckj/sfaa265]

  • Downie ML, Gupta S, Tekman MC, Cheshire C, Arora S, Licht C, Robinson LA, Munoz M, Alvaro Madrid Aris, Al Attrach I, Brenchley PE, Gale DP, Stanescu H, Bockenhauer D and Kleta R.

    Identification of a Locus on the X Chromosome Linked to Familial Membranous Nephropathy.

    Kidney International Reports . 6(6): 1669-1676. Nº de cites: 1

    [doi:10.1016/j.ekir.2021.02.025]

  • Tanaka K, Adams B, Alvaro Madrid Aris, Fujita N, Ogawa M, Ortiz S, Vallee M and Greenbaum LA.

    The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

    PEDIATRIC NEPHROLOGY . 36(4): 889-898. Nº de cites: 58

    [doi:10.1007/s00467-020-04774-2]